what I’m saying essentially here is that they will need to be talented and clever in gaining market share - they will need to engage with regulators to point out the epidemiological - immediate and long term advantages of this type of screening - because they are offering an innovation - just like NAN. In terms of hard numbers IMHO on track for 44% of the revenue of NAN - same annuity style type of revenue, we should see the SP head towards $6.80 - $7.50
These posts are more for me - because it is quiet on the ‘news front’ I do not want to do what I did with XRO! and sell off before the re-rate FYI XRO still making negligible profits
what I’m saying essentially here is that they will need to be...
Add GSS (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
69.0¢ |
Change
-0.025(3.50%) |
Mkt cap ! $156.5M | |||
| Open | High | Low | Value | Volume |
| 68.5¢ | 69.0¢ | 68.5¢ | $13.72K | 20.03K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8524 | 69.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 71.5¢ | 3598 | 2 |
View Market Depth
| Last trade - 15.44pm 15/11/2024 (20 minute delay) ? |
| GSS (ASX) Chart |